Takeda Pharmaceutical Company Limited (Takeda) announced the exercise of its option to acquire Adaptate Biotherapeutics (Adaptate), a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery…